Journal News

How is myelin made?

Understanding the protective coating on neurons may inform future therapies
Nuala Del Piccolo
April 14, 2020

Myelin is the protective lipid sheath wrapped around a nerve. It functions as an insulator, akin to the protective coating on a wire, speeding up electrical transmission of signals along a neuron. Myelin also plays a role in maintaining the health of neurons. Myelin function is dysregulated in many neurological disorders, including multiple sclerosis.

Jennifer Siow
This artist’s rendition, created by the first author's daughter, shows neurons with (right) and without (left) a myelin sheath. The neuron with a myelin sheath functions at full capacity, while a neuron without myelin is unhealthy. Oligodendrocytes are depicted in red.

Oligodendrocytes are the myelin-producing cells of the central nervous system. The myelin sheath around a neuron is part of an oligodendrocyte’s plasma membrane, and a single oligodendrocyte can myelinate as many as 50 neurons. During myelination, an oligodendrocyte stretches out tubes of membrane in search of a neuron. When it finds one, it sends the necessary building materials down the tubes and, still operating from a distance, assembles a myelin sheet around the neuron: Composition, number of wraps and total coverage all matter. A myelinated neuron that loses its coating cannot transmit electrical signals properly, leading to loss of muscle control and other neurological problems. 

The myelin sheath is mostly made of lipids, including sphingolipids, which are critical to myelin’s structure and function. The enzyme serine palymitoyltransferase, or SPT, produces the backbone of all sphingolipids, and the membrane-bound protein ORMDL monitors sphingolipid levels and regulates SPT activity. ORMDL’s activity must be precise: Too little sphingolipid production impedes myelination, and too much can be toxic. 

Binks Wattenberg, a professor of biochemistry and molecular biology at Virginia Commonwealth University, studies membrane biogenesis and now focuses on lipid biogenesis. “I am very curious about how the cell knows when to make sphingolipid and when to stop,” Wattenberg said. “I think ORMDL might be the key to answering that question.” 

Wattenberg’s next-door lab neighbor, Carmen Sato–Bigbee, a professor in the same department, studies myelination, with a focus on oligodendrocytes. The two joined forces to study the role of sphingolipid biosynthesis in myelination in developing brains, and reported their results in the Journal of Lipid Research

To uncover the dynamics of sphingolipid content and synthesis during myelination, Wattenberg and Sato–Bigbee’s team worked with newborn rat brains, because peak myelination occurs directly after birth. Only one in five cells in the brain is an oligodendrocyte, so the team isolated these myelin-producing cells for their experiments. 

The researchers found that a large portion of the sphingolipids present in oligodendrocytes during myelination have an atypically long backbone — an 18-carbon chain instead of a 16-carbon chain. “The 18-carbon chain backbone points to a change in lipid composition during myelination, which might explain the insulating properties of myelin,” Wattenberg said. “In future work, we want to look at the role of each type of sphingolipid in myelination.”

The study also found that SPT activity increases for the first few days of myelination and then begins to decrease. ORMDL activity is not measurable, but the team deduced that ORMDL isoform expression varies over time. These findings pave the way for future experiments. 

“The control of sphingolipid biosynthesis is key to myelination, and understanding how this process works will enable us to alter it in future treatments,” Wattenberg said. “Our pie-in-the-sky goal is to understand sphingolipid biosynthesis so well that we can reprogram oligodendrocytes and reverse demyelination in degenerative myelination diseases like MS.”

 

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Nuala Del Piccolo

Nuala Del Piccolo is a scientific writer at Imperial College London. She earned her B.S. in biomedical engineering and Ph.D. in materials science at Johns Hopkins University.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Computational tool helps scientists create novel bug sprays
Journal News

Computational tool helps scientists create novel bug sprays

May 20, 2025

Rapid discovery of mosquito repellent compounds is enabled through a novel screening platform that combines both computational modeling and functional screening.

Meet Lan Huang
Interview

Meet Lan Huang

May 19, 2025

Molecular & Cellular Proteomics associate editor uses crosslinking mass spec to study protein–protein interactions to find novel therapeutics.

Influenza gets help from gum disease bacteria
Journal News

Influenza gets help from gum disease bacteria

May 15, 2025

Scientists discover that a protease from Porphyromonas gingivalis enhances viral spread. Read more about this recent Journal of Biological Chemistry paper.

How bacteria fight back against promising antimicrobial peptide
Journal News

How bacteria fight back against promising antimicrobial peptide

May 15, 2025

Researchers find a mutation in E. coli that reduces its susceptibility to a potential novel antibiotic. Read more about this recent Journal of Biological Chemistry paper.

New clues reveal how cells respond to stress
Journal News

New clues reveal how cells respond to stress

May 15, 2025

Redox signaling protein may help regulate inflammasome and innate immune activation. Read more about this recent Journal of Biological Chemistry paper.

Innovative platform empowers scientists to transform venoms into therapeutics
Journal News

Innovative platform empowers scientists to transform venoms into therapeutics

May 13, 2025

Scientists combine phage display and a “metavenome” library to discover new drugs that bind clinically relevant human cell receptors. Read about this recent Molecular & Cellular Proteomics paper.